Phase 1 Study of STRO-006 in Adults With Refractory Solid Tumors That Are Recurrent or Metastatic

This study is a first-in-human (FIH) Phase 1 open-label, multicenter study including three parts: * Part 1A is a dose escalation of STRO-006 monotherapy in selected tumor types reported to commonly express ITGB6. Part 1A will determine the safety, tolerability, pharmacokinetics (PK), and preliminary anti-tumor activity of STRO-006. * Part 1B is a dose expansion in one or more indications, as determined by the Sponsor, to further evaluate a STRO-006 monotherapy dose, examine anti-tumor activity, and determine the recommended Phase 2 dose (RP2D) of STRO-006 monotherapy. * Part 1C is a combinati

Trial Details

NCT ID
NCT07807345
Phase
PHASE1
Sponsor
Sutro Biopharma, Inc.
Status
RECRUITING
Cancer Type
Uterine Cancer
Interventions
  • STRO-006
  • Pembrolizumab
Locations (sample)
  • Orlando, Florida, United States|28.53834,-81.37924
  • Boston, Massachusetts, United States|42.35843,-71.05977
  • Oklahoma City, Oklahoma, United States|35.46756,-97.51643
  • Irving, Texas, United States|32.81402,-96.94889
  • Lubbock, Texas, United States|33.57786,-101.85517

Key Eligibility Criteria

  • Histologically or cytologically documented refractory solid tumors that are recurrent or metastatic including: HNSCC (excluding EBV-positive nasoph…
  • Age ≥ 18 years
  • Life expectancy of at least 3 months
  • Willingness and ability to comply with the study protocol and long

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Cancer Trials on Trialify →